ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE
REGULATED INFORMATION Positive Phase III results with caplacizumab and a successful U.S. IPO GHENT, Belgium, 16 November 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced its non-audited financial results for the first nine months of …